Nov 17, 2020

Chugai Selected for the First Time in the “DJSI World,” a Global ESG Investment Index

  • Chugai has been recognized as a highly sustainable company and ranked third in the world as a pharmaceutical company
  • Selected for the first time in the "DJSI World" comprised of the top eight sustainable pharmaceutical companies in the world
  • Selected as "DJSI Asia Pacific" for the sixth time for three consecutive years

TOKYO, November 17, 2020 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the company has been selected for the first time as a constituent of "Dow Jones Sustainability Indices (DJSI) World," the global version of DJSI, which is the world's leading ESG investment index. Furthermore, Chugai has been selected as a constituent of "DJSI Asia Pacific," the Asia-Pacific version, for the sixth time for three consecutive years.

DJSI is a leading ESG index developed by S&P Dow Jones Indices (USA) and is one of the main investment selection criteria for investors worldwide who are interested in corporate sustainability. Companies are selected annually as a constituent based on the sustainability assessment in terms of corporate economic, environmental and social aspects.

In the pharmaceutical sector of the "DJSI World," the top eight sustainable companies have been selected as constituents, including Chugai, which received the third highest sustainability rating among pharmaceutical companies in the world. 323 companies (including 39 Japanese companies) have been selected for the DJSI World in total. Five companies including Chugai, have been selected for "DJSI Asia Pacific," the Asia-Pacific version of DJSI.

In the mid-term business plan IBI 21 which runs for three years starting from 2019, Chugai has set “Strengthen Sustainable Platforms” as one of the five strategies that support our challenge toward innovation. We have specified six priority areas to realize the creation of shared values with society. Based on the gap analysis of external ESG assessments such as DJSI, we are working to continuously strengthen the sustainable platforms by implementing the PDCA cycle centered on the above six areas. As a result, this year's sustainability scores of human rights due diligence for suppliers and supply chain management far exceeded last year.

Based on the business philosophy of “Innovation all for the patients,” Chugai is committed to actively fulfill our social responsibilities as a healthcare company by adding exceptional value through the creation of innovative medical products and services for the benefit of the medical community and human health around the world.

Contact:

  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Tomoko Shimizu
  • Tel: +81-3-3273-0881
  • E-mail: pr@chugai-pharm.co.jp
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Toshiya Sasai
  • Tel: +81-3-3273-0554
  • E-mail: ir@chugai-pharm.co.jp
  • Like
  • Tweet
  • LINE it!
  • E-mail
Back to top